Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
MarketBeat on MSN5h
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study
Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its in-development weight loss drug CagriSema.
STAT5h
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
Hikma looks to launch generic versions of Novo Nordisk diabetes drugs, FT says
Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...
Novo Nordisk's Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...